The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
Hagop M. Kantarjian
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Dong-Wook Kim
No relevant relationships to disclose
Javier Pinilla-Ibarz
Consultant or Advisory Role - ARIAD
Honoraria - ARIAD
Philipp D. Le Coutre
Honoraria - Bristol-Myers Squibb; Novartis
Ronald Paquette
Consultant or Advisory Role - ARIAD
Honoraria - ARIAD
Charles Chuah
Honoraria - Bristol-Myers Squibb; Novartis
Franck E. Nicolini
Consultant or Advisory Role - Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
Jane Apperley
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Hanna Jean Khoury
No relevant relationships to disclose
Moshe Talpaz
Consultant or Advisory Role - ARIAD; Novartis
Honoraria - ARIAD
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
John F DiPersio
No relevant relationships to disclose
Michele Baccarani
Consultant or Advisory Role - ARIAD; Novartis
Honoraria - ARIAD; Novartis
Stephanie Lustgarten
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Frank G. Haluska
Employment or Leadership Position - ARIAD
Consultant or Advisory Role - ARIAD (I)
Stock Ownership - ARIAD
Honoraria - Lia Gore (I)
Research Funding - ARIAD
Francois Guilhot
Consultant or Advisory Role - ARIAD
Honoraria - ARIAD
Michael W.N. Deininger
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Research Funding - Bristol-Myers Squibb; Celgene; Genzyme; Novartis; YM BioSciences
Andreas Hochhaus
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; MSD; Novartis; Pfizer
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Neil P. Shah
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb
Research Funding - ARIAD; Bristol-Myers Squibb
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva